Investors' Soapbox PM

A Genius Move by Agenus

An acquisition by Novartis shows that Agenus found a bargain.

February 19, 2014

Maxim Group

Novartis has acquired privately held CoStim for undisclosed terms.

CoStim gives Novartis (ticker: NVS) access to anti-PD2, LAG3 and TIM3 checkpoint inhibitors. It is our understanding that Novartis may have made significant upfront payments ($500 million), but we have not been able to validate this information. While we have...